Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 11, Number 8—August 2005


Cephalosporin-resistant Pneumococci and Sickle Cell Disease

Martha L. Miller*1, Caroline A. Obert*1, Geli Gao*, Najat C. Daw*, Patricia Flynn*, and Elaine Tuomanen*Comments to Author 
Author affiliations: *St. Jude Children's Research Hospital, Memphis, Tennessee, USA

Main Article

Table 1

Distribution of β-lactam resistance in nasopharyngeal pneumococcal isolates from sickle cell disease patients

Penicillin susceptibility* No. isolates Cefotaxime susceptibility* No. isolates
Sensitive 31 Sensitive 31
Intermediate 24 Sensitive 19
Intermediate 3
Resistant 2
Resistant 9 Intermediate 3
Resistant 6

*Definition of susceptibility per Clinical and Laboratory Standards Institute (formerly NCCLS) guidelines from 1994 and 1995 (10,11). Sensitive, penicillin V MIC<0.06 μg/mL, cefotaxime MIC<0.05 μg/mL; intermediate, penicillin V MIC 0.12–1 μg/mL, cefotaxime MIC 1 μg/mL; resistant, penicillin or cefotaxime MIC>2 μg/mL.

Main Article

1These authors contributed equally to this study.

Top of Page The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO